Status:

COMPLETED

Risk Factors and Application of Risk Management Strategies in Hemodialysis Patients Complicated With Heart Failure

Lead Sponsor:

Guiren Hou

Conditions:

Hemodialysis

Heart Failure

Eligibility:

All Genders

38-68 years

Phase:

NA

Brief Summary

Age, hyperglycemia, inflammation, and comorbidities (hypertension, diabetes, coronary disease) independently increase HF risk in hemodialysis patients. Targeted risk management reduces psychological d...

Detailed Description

To identify risk factors for heart failure (HF) in hemodialysis patients and assess the efficacy of targeted risk management strategies in improving prognosis and care quality. A total of 170 hospital...

Eligibility Criteria

Inclusion

  • Patients were aged 18 years or older who had been undergoing regular hemodialysis treatment for more than three months.
  • Patients were in good cardiopulmonary health without severe acute or chronic diseases, and were capable of undergoing the study-related examinations and treatments.
  • Patients had not undergone major surgeries or experienced acute complications within the three months prior to enrollment, and their conditions were stable.
  • Patients demonstrated high compliance by following medical advice and regularly attending dialysis sessions and related examinations.
  • ⑤Patients were able to understand the study objectives, had signed the informed consent form, and were willing to cooperate with follow-up visits and long-term observation.

Exclusion

  • Patients were excluded if they had severe liver diseases (e.g., cirrhosis or liver failure), significant systemic infections, active tuberculosis, malignant tumors, connective tissue diseases, or other major illnesses.
  • Patients with congenital kidney diseases, congenital heart defects, or other severe congenital structural abnormalities were excluded.
  • Patients who had a documented history of severe cardiac diseases were excluded, including those with primary/secondary cardiomyopathy, valvular heart disease, myocarditis, or pericardial diseases.
  • Patients were excluded if they had severe mental disorders or cognitive impairments that prevented their cooperation with study assessments or treatments.
  • ⑤Patients whose clinical records or examination data were incomplete, thereby precluding effective analysis, were excluded.

Key Trial Info

Start Date :

January 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2024

Estimated Enrollment :

170 Patients enrolled

Trial Details

Trial ID

NCT06959927

Start Date

January 1 2022

End Date

January 30 2024

Last Update

May 7 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Changsha Fourth Hospital

Changsha, China